



# **Overview**

The advances in cancer therapeutics has significantly improved cancer survival. With cancer mortality decreasing, cardiovascular disease has emerged as a formidable competing cause of death. Cancer survivors now demonstrate 2-5 times higher mortality risk due to cardiovascular disease than the general population, threatening to limit the gains achieved in cancer survival.

In response to the growing concerns about the cardiovascular challenges faced by patients with cancer, the **field of Cardio-Oncology has evolved**, consisting of experts in both cancer and cardiovascular medicine working to improve the detection, monitoring, and treatment of cardiovascular disease at each stage of the cancer care continuum. The field is rapidly growing to meet the urgent need to improve the cardiovascular health of patients with cancer.

Join us in person in New York City for this **state-of-the-art**, **comprehensive**, **case-based curriculum** addressing critical topics relevant to the cardiovascular health of patients with cancer and cancer survivors. Together, an interdisciplinary group, consisting of **cardiology and oncology experts from Memorial Sloan Kettering Cancer Center and around the <b>world**, will present the latest research and contemporary practice strategies in the prevention, early diagnosis, and management of cardiovascular disease in cancer patients and cancer survivors.

Early rates available through March 1, 2024:

msk.org/CardioOnc

The symposium will include a series of talks **highlighting cutting-edge and trending subjects in the rapidly evolving field of Cardio-Oncology**, ensuring that participants gain insights into the most recent advancements shaping the future of cardiovascular care for cancer patients.

## **Networking Opportunities**

This symposium will offer a forum for networking and professional collaboration. All presentations will include devoted time for interaction between audience members and presenters. Additionally, a **complimentary networking reception** will be held on Thursday, May 2, 2024, following the symposium, to provide an opportunity for the Cardio-Oncology community to interact and get to know each other. Please RSVP for the networking reception during registration. We hope to see you there!

### **Who Should Attend**

This symposium is intended for cardiologists, internists, hematologists/oncologists, advanced practice providers, nurses, housestaff and other affiliated healthcare professionals who are involved in the care of cancer patients or have an interest in the field of cardio-oncology.

## **Online Syllabus**

Attendees will receive access to an online syllabus after the conclusion of the overall symposium. The syllabus will include select PDFs of the faculty presentations (slides) and video recordings of the lectures. The syllabus (PDFs and video recordings) will be available through December 31, 2024.

Early rates available through March 1, 2024:

## **Educational Objectives**

At the conclusion of this symposium, learners will be able to:

- Describe contemporary anti-cancer treatments (such as anthracyclines, targeted therapy, immunotherapy, cellular therapy, radiation), outlining their roles in cancer therapy, mechanisms of action, cardiotoxicity profiles, and their impact on the cardiovascular system
- Determine the strategies for monitoring and managing cardiotoxicity, identifying the evidence and the knowledge gaps
- Explain the diagnostic and treatment strategies for cardiac amyloidosis including advances in therapy
- Demonstrate the principles of the permissive cardiotoxicity strategy and how it applies in specific treatment scenarios
- Summarize the appropriate use of imaging modalities in contemporary Cardio-Oncology, from guidelines to best practices
- State the late cardiovascular sequelae of cancer treatment and the best approach to managing the cardiovascular health of adult survivors of childhood cancer
- Illustrate the challenges of managing acute cardiovascular disease in patients during cancer treatment

## **Symposium Directors**



Jennifer Liu, MD
Chief, Cardiology Service
Professor of Clinical Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College



**Dipti Gupta, MD, MPH**Associate Attending, Cardiology Service
Program Director, Cardio-Oncology
Clinical Research Fellowship
Memorial Sloan Kettering Cancer Center

## **Symposium Planning Committee**



Carol L. Chen, MD
Vice Chair, Quality Assurance
Attending, Cardiology Service
Memorial Sloan Kettering Cancer Center



**Stephanie Feldman, MD**Attending
Assistant Professor of Medicine, Division of Cardiology
New York Presbyterian/Weill Cornell Medical College




Annie Tsay, MD

Cardio-Oncology Fellow

Memorial Sloan Kettering Cancer Center



**Eileen Vella, PA-C**Advanced Practice Provider Manager
Memorial Sloan Kettering Cancer Center



Anthony F. Yu, MD, MS
Associate Attending, Cardiology Service
Associate Professor of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College

## **Invited Symposium Faculty**

#### **Daniel Addison, MD**

Ohio State University Wexner Medical Center Columbus, OH

#### Ana Barac, MD, PhD

Inova Schar Cancer Inova Schar Heart and Vascular Fairfax, VA

#### Anne Blaes, MD, MS

University of Minnesota Minneapolis, MN

#### Stephanie Dixon, MD, MPH

St. Jude Children's Research Hospital Memphis, TN

#### Michael Fradley, MD

University of Pennsylvania Philadelphia, PA

#### Parag Goval, MD

Weill Cornell Medical Center New York, NY

#### **Robert Harrington, MD**

Weill Cornell Medical Center New York, NY

#### Joerg Hermann, MD, PhD

Mayo Clinic Rochester, MN

#### **Kristine Jang, DO**

Stony Brook Medical Center Stony Brook, NY

#### Sahil Khera, MD

Mount Sinai Medical Center New York, NY

#### Ninian Lang, Bsc, MB, ChB, PhD

University of Glasgow Glasgow, Scotland

#### **Daniel Lenihan, MD**

International Cardio Oncology Society Tampa, FL

#### **Teresa Lopez-Fernandez, MD**

La Paz University Madrid, Spain

#### Joshua Mitchell, MD, MSCI

Washington University Medical Center St. Louis, MO

#### Babak Navi, MD, MS

Weill Cornell Medical Center New York, NY

#### **Tomas Neilan, MD, MPH**

Massachusetts General Hospital Boston, MA

#### Jayant Raikhelkar, MD

Columbia University Irving Medical Center New York, NY

#### Marielle Scherrer-Crosbie, MD, PhD

University of Pennsylvania Philadelphia, PA

# Paaladinesh Thavendiranathan, MD, SM, FRCPC, FASE

Peter Munk Cardiac Center, Toronto General Hospital Toronto, Ontario, Canada

#### Jonathan Weinsaft, MD

Weill Cornell Medical Center New York, NY

## **MSK Symposium Faculty**

Angel T. Chan, MD, PhD

Cardiology

Paul Cohen, MD, PhD

Cardiology

Chau T. Dang, MD, MPH

**Breast Oncology** 

Sergio A. Giralt, MD

**Bone Marrow Transplant** 

Michelle N. Johnson, MD, MPH

Cardiology

Ioanna Kosmidou, MD, PhD

Cardiology

Andrew Laccetti, MD

**GU Oncology** 

Heather J. Landau, MD

Myeloma Service

Avi Leader, MD

Benign Hematology

Eileen P. McAleer, MD

Cardiology

Diana Roth O'Brien, MD, MPH

**Radiation Oncology** 

Michael Postow, MD

Melanoma

Sofia Romero-Velez, PA-C

**Advanced Practice Provider** 

Wendy L. Schaffer, MD, PhD

Cardiology

Jessica Scott, PhD

**Exercise Oncology** 

Roni Shouval, MD, PhD

**Bone Marrow Transplant** 

**Dylana Smith, AGPCNP-BC** 

**Advanced Practice Provider** 

Richard M. Steingart, MD

Cardiology

Helena A. Yu, MD

Thoracic Oncology

Jeffrey Zwicker, MD

Benign Hematology

#### MITIGATION OF RELEVANT FINANCIAL RELATIONSHIPS

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

# **Schedule**

# THURSDAY, MAY 2, 2024 ● 7:00 AM — 6:40 PM

7:00 AM Registration and Continental Breakfast

8:00 AM Symposium Welcome and Introduction

Jennifer Liu, MD

Dipti Gupta, MD, MPH

**Cardio-Oncology: Moving the Field Forward** 

MODERATORS: Carol L. Chen, MD • Teresa Lopez-Fernandez, MD

8:10 AM Cardiovascular Disease Burden in Patients with Cancer:

Where and How Cardio-Oncology Can Make a Difference

Joerg Hermann, MD, PhD

8:25 AM Racial and Ethnic Disparities in Cardio-Oncology Care:

A Call to Action to Achieve Health Equity

Michelle N. Johnson, MD, MPH

8:40 AM Panel Discussion and Q&A

Immunotherapy: Evolving Landscape in Diagnosing and Managing Immune Related Cardiotoxicity

MODERATORS: Dipti Gupta, MD, MPH • Joshua Mitchell, MD, MSCI

8:50 AM Fundamentals of Antitumor Immunity and

**Current Applications in Solid Tumor Malignancy** 

Michael Postow, MD

9:05 AM Cardiovascular Toxicity with Immune Checkpoint Inhibitors:

Myocarditis and Beyond Tomas Neilan, MD, MPH

9:20 AM CASE PRESENTATION

**ICI Myocarditis Cases from Mild to Deadly** 

PRESENTER: Annie Tsay, MD

DISCUSSANT: Stephanie Feldman, MD

9:35 AM Panel Discussion

#### **Prostate Cancer and Cardiovascular Disease**

MODERATORS: Stephanie Feldman, MD • Richard M. Steingart, MD

9:55 AM Contemporary Management of Prostate Cancer:

Hormonal Therapy, Radiation, and Surgery — What Factors Influence Treatment Decisions?

Andrew Laccetti, MD

10:10 AM Implications of Cardiovascular Disease in Prostate Cancer

Therapies: How to mitigate CV Risk During ADT

Daniel Lenihan, MD

10:25 AM Panel Discussion and Q&A

10:35 AM Break

# Lung Cancer: Advances in Treatment and Their Impact on Cardiovascular Health

MODERATORS: Anne Blaes, MD, MS • Tomas Neilan, MD, MPH

10:55 AM Contemporary Lung Cancer Diagnosis and Treatment:

A Primer for the Non-Oncologist

Helena A. Yu. MD

11:10 AM Cardiovascular complications Associated with Lung Cancer

**Treatment: Screening, Diagnosis, and Management** 

Anthony F. Yu, MD, MS

11:25 AM Panel Discussion and Q&A

#### **Breast Cancer: Best Practice Strategies to Optimize Outcomes**

MODERATORS: Jennifer Liu, MD • Joerg Hermann, MD, PhD

11:35 AM Updates in the Current Landscape of Contemporary Breast

Cancer Treatment: Immunotherapy, HER2-targeted Therapy,

and Antibody Drug Conjugates

Chau T. Dang, MD, MPH

11:50 AM Cardiotoxicity Associated with Breast Cancer Treatment:

**Updates on Screening and Management** 

Anthony F. Yu, MD, MS

12:05 PM Panel Discussion and Q&A

12:15 PM Lunch Break

12:25 PM - LUNCH BREAKOUT SESSION (Lobby)

1:00 PM How I Started My Cardio-Oncology Practice

MODERATOR: Dipti Gupta, MD, MPH

PANELISTS: Stephanie Feldman, MD • Jayant Raikhelkar, MD •

Kristine Jang, DO

1:10 PM SPECIAL LECTURE



How to Train in Cardio-Oncology: Cardio-Oncology Fellowship Programs Dipti Gupta, MD, MPH

Cardiovascular	<b>Considerations</b>	in Hemato	logic Ma	lignancies
Sui distributioni	- Consider delicities	III I I CIII I I I I		

MODERATORS: Marielle Scherrer-Crosbie, MD, PhD • Michael Fradley, MD

1:25 PM Understanding Stem Cell/Bone Marrow Transplant:

When, for Whom, and Why?

Sergio A. Giralt, MD

1:40 PM Cardiovascular Challenges During and After Bone Marrow

**Transplant: How to Mitigate Adverse Cardiac Events and** 

**Optimize Cardiovascular Health** Wendy L. Schaffer, MD, PhD

1:55 PM CART T Cell Therapy: Navigating a New Frontier and

**Understanding the Cardiovascular Manifestations** 

Roni Shouval, MD, PhD

2:10 PM Cardiovascular Considerations of TKI Therapy in

Chronic Leukemias Daniel Addison, MD

2:25 PM Panel Discussion and Q&A

### **Amyloidosis and Multiple Myeloma:**

### **Contemporary Diagnosis and New Advances in Treatment**

MODERATORS: Jayant Raikhelkar, MD • Jennifer Liu, MD

2:45 PM Multiple Myeloma and AL amyloidosis:

A Primer on Diagnosis and Management

Heather J. Landau, MD

3:00 PM Cardiac Amyloidosis: Unmasking the Great Masquerader —

When to Suspect and How to Diagnose

Jennifer Liu. MD

3:15 PM Managing Patients with TTR Amyloidosis:

**Progress and Challenges** 

Parag Goyal, MD

3:30 PM Panel Discussion and Q&A

3:45 PM Break

#### **Thrombosis and Hemostasis in Cancer**

MODERATORS: Richard M. Steingart, MD • Daniel Addison, MD

4:05 PM **Venous Thromboembolism in Cancer Patients:** 

**Risk Assessment, Prevention and Treatment** 

Jeffrey Zwicker, MD

4:20 PM Cancer-Associated Stroke:

**Etiology, Detection and Management** 

Babak Navi, MD, MS

4:35 PM Cancer Associated Non-Bacterial Thrombotic Endocarditis:

Presentation, Pathophysiology, Management and

**Future Avenues** Avi Leader, MD

4:50 PM Panel Discussion and Q&A

5:05 PM IC-OS: Opportunities for Collaboration, Research,

**and Education**Daniel Lenihan, MD

5:15 PM Closing Remarks

Dipti Gupta, MD, MPH

5:20 PM Adjournment

## **Complimentary Networking Reception**

5:20-6:40 PM • Zuckerman Lobby

Join us for an opportunity to connect and interact with the cardio-oncology community. Hors d'oeuvre and refreshments will be served. RSVP required.

# FRIDAY, MAY 3, 2024 • 7:30 AM — 5:40 PM

7:30 AM Continental Breakfast

8:00 AM DEPARTMENT OF MEDICINE GRAND ROUNDS

**Introduction**Jennifer Liu, MD

8:05 AM



The Future of Clinical Trials:

What I have learned Over 30+ Years as a Trialist

Robert Harrington, MD

8:50 AM Q&A

9:00 AM Symposium Welcome Back and Highlights from Day 1

Eileen Vella, PA-C

#### **Research Progress**

MODERATOR: Anthony F. Yu, MD, MS

9:05 AM A Decade in Review:

**Top Research Studies and Clinical Trials in Cardio-Oncology** 

Ana Barac, MD, PhD

# Role of Imaging Markers and Biomarkers in Cardio-Oncology: Strategies for Early Detection of Cardiotoxicity

MODERATORS: Angel T. Chan, MD, PhD • Eileen P. McAleer, MD

9:25 AM Multimodality Imaging — Which Test, When, and Why?

Marielle Scherrer-Crosbie, MD, PhD

9:40 AM How I Use Strain and Biomarkers in My Practice

Paaladinesh Thavendiranathan, MD, SM, FRCPC, FASE

9:55 AM MR Imaging of Cardiac Masses:

**Clinical Applications and Prognostic Implications** 

Jonathan Weinsaft, MD

10:10 AM Panel Discussion and Q&A

10:40 AM Break

#### **Coronary Artery Disease in Cardio-Oncology**

MODERATORS: Ioanna Kosmidou, MD, PhD • Dipti Gupta, MD, MPH

10:55 AM **5FU Induced Chest Pain:** 

**Diagnostic and Management Algorithm** 

Wendy L. Schaffer, MD, PhD

11:10 AM Optimal Management of Patients with Acute Coronary

**Syndrome and Advanced Cancer** 

Stephanie Feldman, MD

11:25 AM Navigating Cardiac Interventions in Patients with

**Active Cancer: Insights from Evidence and Experience** 

Sahil Khera, MD

11:40 AM Panel Discussion and Q&A

### **Radiation Therapy and the Heart**

MODERATORS: Kristine Jang, DO • Jennifer Liu, MD

11:55 AM Radiation Induced Heart Disease:

A Practical Guide to Diagnosis and Management

Joshua Mitchell, MD, MSCI

12:10 PM Radiation Therapy: Current and Future Strategies to

**Minimize Radiation Induced Cardiotoxicity** 

Diana Roth O'Brien, MD, MPH

12:25 PM Panel Discussion and Q&A

12:35 PM Lunch Break

#### **Cancer Survivorship and Prevention**

MODERATORS: Javant Raikhelkar, MD • Carol L. Chen, MD

1:15 PM Late Onset Cardiotoxicity in Adult Survivors of Childhood

Cancer: Incidence, Risk Factors, and Individual

**Cardiovascular Risk Prediction** Stephanie Dixon, MD, MPH

1:30 PM **Developing a Cancer Survivorship Health Care Model** 

Stephanie Dixon, MD, MPH

1:45 PM Panel Discussion and Q&A

#### **Prevention in Cardio-Oncology**

MODERATORS: Daniel Lenihan, MD • Ana Barac, MD, PhD

1:55 PM Common Risk Factors Between Cancer and

**Cardiovascular Disease** Anne Blaes, MD, MS

2:10 PM Metabolic Issues in Cardio-Oncology:

**Can We Prevent Cancer by Improving Cardiovascular** 

**Risk Factors?** 

Paul Cohen, MD, PhD

2:25 PM Pharmacologic Cardioprotective Strategies to Prevent

Cardiotoxicity. What Have We Learned from the

**Clinical Trials?** 

Jayant Raikhelkar, MD

2:40 PM Prescribing Exercise to Mitigate Cardiovascular Toxicity in

Clinical Practice: What are the Opportunities and Barriers?

Jessica Scott, PhD 😊

2:55 PM Panel Discussion and Q&A

# Best Practices in the Management of Cardiovascular Disease in Patients with Cancer

MODERATORS: Ninian Lang, Bsc, MB, ChB, PhD •

Paaladinesh Thavendiranathan, MD, SM, FRCPC, FASE

3:15 PM **2022 ESC Cardio-Oncology Guidelines:** 

Is There Evidence to Identify Who Is at High Risk?

Teresa Lopez-Fernandez, MD

3:30 PM **Cancer Therapy-Related HTN:** 

**Optimal Strategy to Achieve Effective BP Control** 

Ninian Lang, Bsc, MB, ChB, PhD

3:45 PM Cancer Therapy-Related Cardiac Dysfunction and Heart Failure:

Do the Traditional Paradigms Apply?

Ana Barac, MD, PhD

4:00 PM **Striking the Balancing:** 

**Navigating Permissive Cardiotoxicity in Cancer Treatment** 

CASE PRESENTERS: Sofia Romero-Velez, PA-C •

Dylana Smith, AGPCNP-BC

DISCUSSANTS: Carol L. Chen, MD • Anthony F. Yu, MD, MS •

Jennifer Liu, MD

4:20 PM Panel Discussion and Q&A

4:35 PM Break

### **Electrophysiology in Cardio-Oncology**

MODERATORS: Richard M. Steingart, MD • Dipti Gupta, MD, MPH

4:50 PM Atrial Fibrillation and Cancer:

**Pathophysiology and Management Algorithm** 

Ioanna Kosmidou, MD, PhD

5:05 PM How to Manage Patients with Cardiac Implantable Devices

**During Radiation/MRI**Michael Fradley, MD

5:20 PM Panel Discussion and Q&A

5:35 PM **Symposium Closing Remarks** 

Dipti Gupta, MD, MPH

5:40 PM Adjournment

Join the conversation with us using the hashtag

#MSKCardioOncCME

@MSKCME • @MSKCancerCenter

# **Accreditation**

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **16.50 AMA PRA Category 1 Credits**  $^{TM}$ **.** Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### MOC/CC RECOGNITION STATEMENTS

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

16.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (**ABIM**) Maintenance of Certification (MOC) program; and

16.50 CME and Self-Assessment requirements of the American Board of Surgery's (**ABS**) Continuous Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABS MOC/CC credit.







# Early rates available through March 1, 2024:

# msk.org/CardioOnc

#### **REGISTRATION FEES**

Registration Type	Early*	General	
Physicians (MDs, PhDs, and DOs)	\$500	\$600	
Advanced Practice Providers	\$350	\$450	
Nurses and Other Healthcare Providers	\$300	\$400	
Residents, Fellows, and Students	\$100**	\$200	
Industry Professionals***	\$950	\$1,050	
MSK Employees	Complimentary		

Program registration includes continental breakfast, lunch, refreshment breaks, and a complimentary invitation to the networking reception.

**MSK Alumni and MSK Cancer Alliance Members:** A discounted registration rate is offered to MSK Alumni and MSK Cancer Alliance members for all CME programs at MSK.

- \*Apply promotion code CARDELY24 during registration to take advantage of early discounted rates. Offer valid through March 1, 2024.
- \*\* Please note the resident, fellow, and student early rate is non-refundable.
- \*\*\*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Visit msk.org/CardioOnc for additional details, including our cancellation policy.

